CALA
Calithera Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
Calithera Biosciences, Inc. (CALA) is rated C (2.3/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Momentum (B); its weakest is Revisions (D). The rating has held at C for 13 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2021-09-30 | C+ (2.5) | C+ (2.5) | D+ (1.8) | B (3.3) | D (1.5) | C (2.3) |
| 2021-06-30 | C+ (2.5) | C+ (2.5) | D+ (1.8) | B (3.3) | D (1.5) | C (2.3) |